RESUMEN
The impact of COVID-19 on paracoccidioidomycosis (PCM) in Argentina and the consequences generated by the pandemic are discussed. From 2018 to 3 years after the pandemic declaration, 285 proven PCM patients were registered. No association between both diseases was documented. PCM frequency decreased to extremely low levels in 2020. Mandatory social isolation and the emotional and psychological effects generated under pandemic circumstances led to delays in diagnosis, severe disseminated cases, and other challenges for diagnosis in subsequent years. Probable underdiagnosis should be considered due to the overlap of clinical manifestations, the low index of suspicion and the lack of sensitive diagnostic tools.
Asunto(s)
COVID-19 , Paracoccidioidomicosis , Paracoccidioidomicosis/epidemiología , Paracoccidioidomicosis/diagnóstico , Paracoccidioidomicosis/complicaciones , Humanos , COVID-19/epidemiología , COVID-19/complicaciones , Argentina/epidemiología , Masculino , Adulto , Persona de Mediana Edad , Femenino , SARS-CoV-2 , Anciano , Adulto Joven , Pandemias , Adolescente , Diagnóstico TardíoRESUMEN
Information on paracoccidioidomycosis (PCM) in Argentina is fragmented and has historically been based on estimates, supported only by a series of a few reported cases. Considering the lack of global information, a national multicentric study in order to carry out a more comprehensive analysis was warranted. We present a data analysis including demographic and clinical aspects of a historical series of 466 cases recorded over 10 years (2012-2021). Patients were aged from 1 to 89 years. The general male: female (M:F) ratio was 9.5:1 with significant variation according to the age group. Interestingly, the age range 21-30 shows an M:F ratio of 2:1. Most of the cases (86%) were registered in northeast Argentina (NEA), showing hyperendemic areas in Chaco province with more than 2 cases per 10,000 inhabitants. The chronic clinical form occurred in 85.6% of cases and the acute/subacute form occurred in 14.4% of cases, but most of these juvenile type cases occurred in northwestern Argentina (NWA). In NEA, the incidence of the chronic form was 90.6%; in NWA, the acute/subacute form exceeded 37%. Diagnosis by microscopy showed 96% positivity but antibody detection displays 17% of false negatives. Tuberculosis was the most frequent comorbidity, but a diverse spectrum of bacterial, fungal, viral, parasitic, and other non-infectious comorbidities was recorded. This national multicenter registry was launched in order to better understand the current status of PCM in Argentina and shows the two endemic zones with a highly diverse epidemiology.
RESUMEN
COVID-19-associated pulmonary aspergillosis (CAPA) incidence varies depending on the country. Serum galactomannan quantification is a promising diagnostic tool since samples are easy to obtain with low biosafety issues. A multicenter prospective study was performed to evaluate the CAPA incidence in Argentina and to assess the performance of the lateral flow assay with digital readout (Sona Aspergillus LFA) as a CAPA diagnostic and screening tool. The correlation between the values obtained with Sona Aspergillus LFA and Platelia® EIA was evaluated. In total, 578 serum samples were obtained from 185 critically ill COVID patients. CAPA screening was done weekly starting from the first week of ICU stay. Probable CAPA incidence in critically ill patients was 10.27% (19/185 patients when LFA was used as mycological criteria) and 9% (9/100 patients when EIA was used as mycological criteria). We found a very good correlation between the two evaluated galactomannan quantification methods (overall agreement of 92.16% with a Kappa statistic value of 0.721). CAPA diagnosis (>0.5 readouts in LFA) were done during the first week of ICU stay in 94.7% of the probable CAPA patients. The overall mortality was 36.21%. CAPA patients' mortality and length of ICU stay were not statistically different from for COVID (non-CAPA) patients (42.11 vs 33.13% and 29 vs 24 days, respectively). These indicators were lower than in other reports. LFA-IMMY with digital readout is a reliable tool for early diagnosis of CAPA using serum samples in critically ill COVID patients. It has a good agreement with Platelia® EIA. LAY SUMMARY: The incidence of COVID-associated pulmonary aspergillosis (CAPA) in critically-ill Argentinian patients was established (10.27%). Serum galactomannan quantification was useful as a screening tool for this mycosis. A good agreement between Platelia® EIA and Sona Aspergillus LFA is reported.
Asunto(s)
COVID-19 , Aspergilosis Pulmonar Invasiva , Aspergilosis Pulmonar , Animales , Argentina/epidemiología , Aspergillus , COVID-19/diagnóstico , COVID-19/veterinaria , Enfermedad Crítica , Galactosa/análogos & derivados , Humanos , Aspergilosis Pulmonar Invasiva/diagnóstico , Aspergilosis Pulmonar Invasiva/veterinaria , Mananos , Estudios Prospectivos , Aspergilosis Pulmonar/diagnóstico , Aspergilosis Pulmonar/veterinaria , Sensibilidad y EspecificidadRESUMEN
Paracoccidioidomycosis (PCM) is a life-threatening systemic mycosis widely reported in the Gran Chaco ecosystem. The disease is caused by different species from the genus Paracoccidioides, which are all endemic to South and Central America. Here, we sequenced and analyzed 31 isolates of Paracoccidioides across South America, with particular focus on isolates from Argentina and Paraguay. The de novo sequenced isolates were compared with publicly available genomes. Phylogenetics and population genomics revealed that PCM in Argentina and Paraguay is caused by three distinct Paracoccidioides genotypes, P. brasiliensis (S1a and S1b) and P. restrepiensis (PS3). P. brasiliensis S1a isolates from Argentina are frequently associated with chronic forms of the disease. Our results suggest the existence of extensive molecular polymorphism among Paracoccidioides species, and provide a framework to begin to dissect the connection between genotypic differences in the pathogen and the clinical outcomes of the disease.
Asunto(s)
Variación Genética/genética , Genómica , Paracoccidioides/genética , Paracoccidioidomicosis/genética , Argentina/epidemiología , Ecosistema , Genética de Población , Genoma Fúngico/genética , Genotipo , Humanos , Paracoccidioides/clasificación , Paracoccidioides/patogenicidad , Paracoccidioidomicosis/clasificación , Paracoccidioidomicosis/epidemiología , Paracoccidioidomicosis/microbiología , Paraguay/epidemiología , FilogeniaRESUMEN
Se presenta un paciente masculino, de 63 años de edad, con antecedentes de enfermedad de Leriche y colocación de prótesis vascular. Es internado en terapia intensiva por infarto intestinal e isquemia aguda de miembro inferior derecho por lo cual es intervenido quirúrgicamente. Mediante el hallazgo de Paracoccidioides sp en prótesis vascular y otros órganos internos, asociados a lesiones cutáneas y compromiso pulmonar, se realiza el diagnóstico de paracoccidioidomicosis crónica multifocal. Destacamos el compromiso de la prótesis como parte de la diseminación fúngica (AU)
A 63-year-old male patient with a history of Leriche disease and vascular prosthesis placement is reported. He is admitted to intensive care unit with intestinal infarct and acute ischemia of his right lower limb for which he underwent surgery. Paracoccidioides sp findings in vascular prostheses and other internal organs, associated with skin lesions and pulmonary involvement, allowed the diagnosis of chronic multifocal paracoccidioidomycosis. We emphasize the commitment of the prosthesis as part of fungal dissemination on this case (AU)